ArticleCVIR endovascular2026
Clinical outcomes of bleomycin electrosclerotherapy (BEST) for the treatment of slow-flow vascular malformations (SFVMs): a UK single-centre experience.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBleomycin Electrosclerotherapy (BEST) is an emerging treatment for slow-flow vascular malformations (SFVMs), utilising electroporation to enhance intralesional bleomycin uptake. This study evaluates the safety and clinical outcomes of BEST in reducing symptom severity (SS) and improving quality-of-life (QoL) in patients with SFVMs.
methodsThis retrospective, single-centre study analysed 20 consecutive patients with symptomatic SFVMs treated with BEST between September 2022 and November 2024. Patients underwent SS and QoL treatment specific questionnaires before treatment and at follow-up (mean: 286 days). Intralesional bleomycin injection was immediately followed by electroporation in every case.
resultsA total of 42 BEST procedures were performed, on the following anatomical areas: Face: 14 (70%), Neck: 2 (10%), Leg: 3 (15%), Arm: 1 (5%). Significant reduction in the mean SS (-8.2, p < 0.001) and QoL (-5.2, p < 0.001) scores was observed. The most improved domains were swelling (mean -2, p < 0.001), aesthetic concerns (mean -2, p < 0.001), and pain (mean -1.1, p < 0.003). No major complications were reported. Skin changes (needle marks) were reported in 13/20, and intra-oral ulcers occurred in 6/20 patients. Most skin changes were either fading away or resolved at follow up. All intra-oral ulcers resolved during follow up.
conclusionsBEST is a safe procedure and demonstrates significant symptom relief and QoL enhancement, particularly in patients with severe baseline symptoms and more conspicuous lesions. While multiple treatments yielded greater improvements, even a single treatment was effective. Post-procedural side effects were minor, the most severe being skin markings and self-limiting ulceration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.